Browse all clinical evidence, news, and expert commentary
A study of 1.4 million women in England shows that pregnancy records should be part of heart health discussions, not just antenatal notes.
A London study of nearly 159,000 patients indicates the programme might do more than just spot high blood pressure early.
Iatrogenic menopause is associated with a higher risk of cardiovascular disease, while menopause before 45 is associated with higher cardiovascular and all-cause mortality.
Children who met criteria for a psychiatric disorder in 2017 were more likely to see difficulties worsen over three years than earlier cohorts. A new England study underlines the importance of prevention, early identification and effective support.
97.3% sensitivity, 94.1% specificity, and NICE still calls its accuracy in primary care unclear. Here is why both things are true.
Three practices searched their records for patients on long-term PPIs and invited them for a capsule sponge test. Nearly 9 in 10 eligible, interested patients took it. About 1 in 25 had Barrett’s oesophagus.
Dr Fatima Tahir explains the safeguards that underpin clinical trials in general practice, from ethical review and informed consent to Good Clinical Practice and ongoing safety monitoring.
A large US matched cohort found lower recorded cerebrovascular, hospital-use and mortality outcomes among people with OSA exposed to GLP-1 receptor agonists. The finding is promising, but observational and not a replacement for standard OSA care.
Preclinical studies show sustained molecular responses to GLP-1 receptor stimulation in pancreatic cell models. What does that mean for primary care, and what does it not show?
The February 2026 NG28 update rewrote type 2 diabetes care for UK GPs. What changed, why it matters, and the four other NICE updates from the past year worth knowing.
This is a chance for women to get their mojo back.
Coding, registers and the four pillars in UK primary care
NICE TA1152 establishes semaglutide 2.4 mg as a secondary cardiovascular-prevention treatment for adults with established cardiovascular disease and a BMI of at least 27 kg/m². Niraj Lakhani considers what this means for primary care.
New MASH licences clarify the fibrosis stages they cover, while the staging pathway remains the practical question for primary care.
CKD is common, but progression is not inevitable.
A BMJ network meta-analysis of 262 trials and 99,791 participants compares 19 obesity drugs. The ranking matters less than what sits behind each position.
